Epizyme, Inc. (EPZM)

NASDAQ: EPZM · IEX Real-Time Price · USD
0.954
-0.003 (-0.31%)
At close: Jun 24, 2022 4:00 PM
0.900
-0.054 (-5.660%)
After-hours: Jun 24, 2022 5:41 PM EDT
-0.31%
Market Cap 157.29M
Revenue (ttm) 38.49M
Net Income (ttm) -236.35M
Shares Out 164.88M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,675,961
Open 0.969
Previous Close 0.957
Day's Range 0.860 - 0.980
52-Week Range 0.410 - 9.860
Beta 1.29
Analysts Buy
Price Target 5.22 (+447.2%)
Earnings Date Aug 8, 2022

About EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell l... [Read more...]

Industry Biotechnology
IPO Date May 31, 2013
CEO Robert Bazemore
Employees 250
Stock Exchange NASDAQ
Ticker Symbol EPZM
Full Company Profile

Financial Performance

In 2021, Epizyme's revenue was $37.43 million, an increase of 137.45% compared to the previous year's $15.76 million. Losses were -$251.12 million, 8.39% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EPZM stock is "Buy." The 12-month stock price forecast is 5.22, which is an increase of 447.17% from the latest price.

Price Target
$5.22
(447.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Hot Penny Stocks Under $1 To Watch In June

Penny stocks to watch under $1 right now The post Hot Penny Stocks Under $1 To Watch In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: NRXPSPPITRVN

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lympho...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients aga...

Epizyme To Participate in H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against n...

Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates

Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates.

Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against n...

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Other symbols: BHCCPRXEXELRETA

Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock?

Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Epizyme Announces Date of First Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against ...

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against n...

Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against n...

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates.

Epizyme to Participate in Upcoming Healthcare Conferences in March

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic tar...

Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer against novel epig...

Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...

Is a Surprise Coming for Epizyme (EPZM) This Earnings Season?

Epizyme (EPZM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Shares of Epizyme Soared 32.1% This Week

The small biopharmaceutical company bounced back after its shares lost half their value the week before.

3 Hot Penny Stocks to Watch Under $4 Right Now

Here are three penny stocks to check out today The post 3 Hot Penny Stocks to Watch Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: IINNSENS

Insiders Buying Pixelworks And 4 Other Penny Stocks

The Euro surged to $1.13 against the US dollar this morning after recent data showed the Eurozone inflation increased to a new record high of 5.1% in January. Investors, meanwhile, focused on some notab...

Other symbols: PXLWAXDXJSDAKNWN

Down 54.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Epizyme (EPZM)

The heavy selling pressure might have exhausted for Epizyme (EPZM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r...